Peptide
Cerebrolysin
SaveA porcine brain-derived peptide preparation containing neurotrophic-factor-like peptides, approved in several countries for stroke and dementia.
Quick verdict
Multiple human trials exist, particularly for stroke recovery and vascular dementia. Cochrane reviews note methodological concerns but some positive signals.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Several RCTs and Cochrane reviews cover stroke and dementia indications. Methodological quality is variable. Approved in ~50 countries but not in the US.
Benefits
- Some RCT evidence for post-stroke cognitive improvement
- Approved in multiple countries for neurological indications
- Generally well tolerated in clinical trials
Dosage notes
Clinical protocols use 10–30 mL IV daily for 10–20 day courses. Must be administered by a clinician.
Side effects
- Injection-site pain
- Dizziness
- Headache
- Rare allergic reactions
Who should be cautious
Biological product derived from animal brain tissue carries theoretical prion risk. Not FDA-approved.
What this page cannot tell you
Cochrane reviews flag high risk of bias in many trials. Effect sizes are modest.
Leaderboard scores
- Memory40
- Recovery35
Write a review
Sign in to write a review.